Journal
TUMOR BIOLOGY
Volume 39, Issue 3, Pages -Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1010428317695013
Keywords
Non-small cell lung cancer; immune checkpoint; cytotoxic T-lymphocyte-associated protein 4; programmed cell death-1; programmed cell death ligand-1; tumor immunotherapy
Categories
Funding
- National Key Technology RD Program [2015BAI12B12]
- Natural Science Foundation of China [81472471, 81272221]
Ask authors/readers for more resources
The treatment of advanced or refractory non-small cell lung cancer has been historically difficult owing to the lack of studies on effective systemic cure. The progress in lung cancer treatment has plateaued, necessitating new options for additional benefits. Immune checkpoint proteins are co-inhibitory factors that can diminish the antigen-specific immune responses by attenuating the regulatory role of cytotoxic T-lymphocyte-associated protein 4, programmed cell death-1, lymphocyte-activation gene 3, and T-cell immunoglobulin mucin-3. The therapeutic strategies targeting immune checkpoints mainly focus on the monoclonal antibody of these regulatory factors, which may facilitate clinical decision making. An enhanced understanding of the drug-resistance mechanisms and the therapeutic efficacy regulation will provide opportunities to improve the clinical outcomes of non-small cell lung cancer patients. Preclinical and clinical trials on these key immune-regulatory agents, which has heralded a new era in immuno-oncology in non-small cell lung cancer treatment, are currently in development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available